|
|
|
|
Santarus Joins the Russell 3000 Index
SAN DIEGO-- (BUSINESS WIRE) -- Santarus, Inc.(NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it is set to join the Russell 3000 Index, which measures the performance of the 3,000 largest U.S. companies based...
|
|
|
Santarus Joins the Russell 3000 Index
Santarus, Inc.(NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it is set to join the Russell 3000 Index, which measures the performance of the 3,000 largest U.S. companies based on total market capitalization....
|
|
|
December 2009 Action Date for Schering-Plough HealthCare Products's OTC ZEGERID New Drug Application
SAN DIEGO--(BUSINESS WIRE)-- Santarus, Inc., a specialty biopharmaceutical company, today announced that , Inc.has received notification from the U.S. Food and Drug Administration (FDA) of a December 2009 action date for an over-the...
|
|
|
FDA to Review Santarus' OTC Heartburn Drug by December
SAN DIEGO (AP) ' Santarus Inc.said Tuesday the proposed over-the-counter version of the heartburn drug Zegerid will be reviewed by the Food and Drug Administration by December. The company's partner, Schering-Plough Corp., is...
|
|
|
Santarus Inc. (SNTS) Announces December 2009 Action Date for Schering-Plough Corporation (SGP)'s OTC ZEGERID N
SAN DIEGO--(BUSINESS WIRE)-- Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA...
|
|
|
Santarus announces Schering-Plough response submission to FDA for OTC Zegerid
SAN DIEGO (Jun.24) Santarus on Tuesday announced that Schering-Plough HealthCare Products has received notification from the Food and Drug Administration of a December 2009 action date for its switch application of the proton-pump...
|
|
|
Santarus Inc. (SNTS) Announces December 2009 Action Date for Schering-Plough HealthCare Products's OTC ZEGERID
SAN DIEGO--(BUSINESS WIRE)-- Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that , Inc. has received notification from the U.S. Food and Drug Administration (FDA) of a December 2009 action date...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Ploughs OTC ZEGERID New Drug Application
- Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA) of a December 2009 action...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Plough's OTC ZEGERID New Drug Application
Source: Santarus, Inc.Buzz up! Companies: SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc! (NASDAQ: SNTS - News), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received...
|
|
|
Santarus Announces December 2009 Action Date for Schering-PloughEURs OTC ZEGERID New Drug Application
Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA) of a December 2009 action...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Plough's OTC ZEGERID New Drug Application
SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc.(NASDAQ: SNTS - News), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Ploughs OTC ZEGERID New Drug Application
Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA) of a December 2009 action...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Plough's OTC ZEGERID New Drug Application
SAN DIEGO (Business Wire) -- Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA...
|
|
|
Santarus Announces December 2009 Action Date for Schering-PloughEURs OTC ZEGERID New Drug Application
SAN DIEGO -- (Business Wire) Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Ploughs OTC ZE
Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA) of a December 2009 action...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Plough's OTC Zegerid New Drug Application
Schering-Plough submitted a New Drug Application (NDA) in March 2008 seeking approval to sell ZEGERID in the U.S.OTC heartburn market. OTC ZEGERID is being developed under the terms of a license agreement signed in October...
|
|
|
Santarus Announces December 2009 Action Date for Schering-PloughEURs OTC ZEGERID New Drug Application
Schering-Plough submitted a New Drug Application (NDA) in March 2008 seeking approval to sell ZEGERID in the U.S.OTC heartburn market. OTC ZEGERID is being developed under the terms of a license agreement signed in October...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Plough's OTC ZEGERID New Drug Application
(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc.has received notification from the U.S. Food and Drug Administration (FDA) of a December 2009 action date for an over...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Plough's OTC ZEGERID New Drug Application
BusinessWire - Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA) of a...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Plough's OTC ZEGERID New Drug Application
SAN DIEGO--(BUSINESS WIRE)-- Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Plough's OTC ZEGERID New Drug Application
SAN DIEGO--(BUSINESS WIRE)-- Santarus, Inc.(NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration (FDA...
|
|
|
SNTS: Schering-Plough Receives December 2009 Action Date for OTC ZEGERID(R)
Ridgeland, MS, JUN 23, 2009 (EventX/Knobias.com via COMTEX) -- SGP | Quote | Chart | News | PowerRating -- By Fain Hughes, fhughes@knobias.com Santarus, Inc.(SNTS) announced that Schering-Plough HealthCare Products, Inc. has received...
|
|
|
Santarus (SNTS) Reports December '09 Action Date for Schering-Plough's (SGP) OTC ZEGERID NDA
Santarus, Inc.(NASDAQ: SNTS) today announced that Schering-Plough (NYSE: SGP) HealthCare Products, Inc. has received notification from the U.S. FDA of a December 2009 action date for an OTC ZEGERID(R) branded omeprazole/sodium...
|
|
|
Santarus Announces December 2009 Action Date for Schering-Plough's OTC ZEGERID New Drug Application
Under the license agreement with Schering-Plough, Santarus is entitled to receive a $20-million milestone upon FDA approval of OTC ZEGERID, a low double-digit royalty on net sales of any OTC ZEGERID product, and may receive up to...
|
|
|
Santarus Reveals Dec. 2009 Action Date For Schering-Plough's OTC ZEGERID New Drug Application - Quick Facts
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Santarus, Inc.(SNTS: News ) announced that Schering-Plough HealthCare Products, Inc. has received notification from the U.S. Food and Drug Administration of a December 2009 action date...
|
